1887

Abstract

[Group A (GAS)] is one of the most important human pathogens, responsible for numerous diseases with diverse clinical manifestations. As the epidemiology of GAS infections evolves, a rapid and reliable characterization of the isolates remains essential for epidemiological analysis and infection control. This study investigated the epidemiological patterns and genetic characteristics of 150 GAS isolates from a tertiary hospital in Lebanon by typing, superantigens (SAgs) detection, PFGE and antibiotic profiling. The results revealed 41 distinct types, the most prevalent of which were 89 (16 %), 12 (10 %), 2 (9 %) and 1 (8 %). Testing for the presence of superantigens showed that (87 %), (36 %) and (30 %) were predominant. PFGE detected 39 pulsotypes when a similarity cut-off value of 80 % was implemented. Antibiotic-susceptibility testing against seven different classes of antibiotics showed that 9 % of the isolates were resistant to clindamycin, 23 % were resistant to erythromycin and 4 % showed the macrolide–lincosamide–streptogramin B (MLS) phenotype. The emergence of tetracycline-resistant strains (37 %) was high when compared with previous reports from Lebanon. This study provided comprehensive evidence of the epidemiology of GAS in Lebanon, highlighting the association between types and toxin genes, and providing valuable information about the origin and dissemination of this pathogen.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.063412-0
2014-09-01
2019-11-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/9/1197.html?itemId=/content/journal/jmm/10.1099/jmm.0.063412-0&mimeType=html&fmt=ahah

References

  1. Ardanuy C., Domenech A., Rolo D., Calatayud L., Tubau F., Ayats J., Martín R., Liñares J.. ( 2010;). Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993–2008). . J Antimicrob Chemother 65:, 634–643. [CrossRef][PubMed]
    [Google Scholar]
  2. Bahnan W., Hashwa F., Araj G., Tokajian S.. ( 2011;). emm typing, antibiotic resistance and PFGE analysis of Streptococcus pyogenes in Lebanon. . J Med Microbiol 60:, 98–101. [CrossRef][PubMed]
    [Google Scholar]
  3. Beall B., Gherardi G., Lovgren M., Facklam R. R., Forwick B. A., Tyrrell G. J.. ( 2000;). emm and sof gene sequence variation in relation to serological typing of opacity-factor-positive group A streptococci. . Microbiol 146:, 1195–1209.
    [Google Scholar]
  4. Chatellier S., Ihendyane N., Kansal R. G., Khambaty F., Basma H., Norrby-Teglund A., Low D. E., McGeer A., Kotb M.. ( 2000;). Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. . Infect Immun 68:, 3523–3534. [CrossRef][PubMed]
    [Google Scholar]
  5. Chiou C. S., Liao T. L., Wang T. H., Chang H. L., Liao J. C., Li C. C.. ( 2004;). Epidemiology and molecular characterization of Streptococcus pyogenes recovered from scarlet fever patients in central Taiwan from 1996 to 1999. . J Clin Microbiol 42:, 3998–4006. [CrossRef][PubMed]
    [Google Scholar]
  6. Ciftci E., Doğru U., Guriz H., Aysev A. D., Ince E.. ( 2003;). Antibiotic Susceptibility of Streptococcus pyogenes strains isolated from throat cultures of children with tonsillopharyngitis. . J Ank Med Sch 25:, 15–20.
    [Google Scholar]
  7. CLSI. ( 2011;). Performance standards for antimicrobial susceptibility testing; 20th Informational Supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute.
    [Google Scholar]
  8. Cole J. N., Barnett T. C., Nizet V., Walker M. J.. ( 2011;). Molecular insight into invasive group A streptococcal disease. . Nat Rev Microbiol 9:, 724–736. [CrossRef][PubMed]
    [Google Scholar]
  9. Commons R., Rogers S., Gooding T., Danchin M., Carapetis J., Robins-Browne R., Curtis N.. ( 2008;). Superantigen genes in group A streptococcal isolates and their relationship with emm types. . J Med Microbiol 57:, 1238–1246. [CrossRef][PubMed]
    [Google Scholar]
  10. Creti R., Imperi M., Baldassarri L., Pataracchia M., Recchia S., Alfarone G., Orefici G.. ( 2007;). emm types, virulence factors, and antibiotic resistance of invasive Streptococcus pyogenes isolates from Italy: what has changed in 11 years?. J Clin Microbiol 45:, 2249–2256. [CrossRef][PubMed]
    [Google Scholar]
  11. Efstratiou A.. ( 2000;). Group A streptococci in the 1990s. . J Antimicrob Chemother 45: (Suppl), 3–12. [CrossRef][PubMed]
    [Google Scholar]
  12. Gracia M., Díaz C., Coronel P., Gimeno M., García-Rodas R., Rodríguez-Cerrato V., del Prado G., Huelves L., Ruiz V.. & other authors ( 2009;). Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European countries, 2005 to 2006: the cefditoren surveillance program. . Diagn Microbiol Infect Dis 64:, 52–56. [CrossRef][PubMed]
    [Google Scholar]
  13. Hraoui M., Boutiba-Ben Boubaker I., Doloy A., Samir E., Ben Redjeb S., Bouvet A.. ( 2011;). Epidemiological markers of Streptococcus pyogenes strains in Tunisia. . Clin Microbiol Infect 17:, 63–68. [CrossRef][PubMed]
    [Google Scholar]
  14. Imöhl M., Reinert R. R., Ocklenburg C., van der Linden M.. ( 2010;). Epidemiology of invasive Streptococcus pyogenes disease in Germany during 2003–2007. . FEMS Immunol Med Microbiol 58:, 389–396.[PubMed]
    [Google Scholar]
  15. Jasir A., Tanna A., Efstratiou A., Schalén C.. ( 2001;). Unusual occurrence of M type 77, antibiotic-resistant group A streptococci in southern Sweden. . J Clin Microbiol 39:, 586–590. [CrossRef][PubMed]
    [Google Scholar]
  16. Kidd T. J., Grimwood K., Ramsay K. A., Rainey P. B., Bell S. C.. ( 2011;). Comparison of three molecular techniques for typing Pseudomonas aeruginosa isolates in sputum samples from patients with cystic fibrosis. . J Clin Microbiol 49:, 263–268. [CrossRef][PubMed]
    [Google Scholar]
  17. Luca-Harari B., Ekelund K., van der Linden M., Staum-Kaltoft M., Hammerum A. M., Jasir A.. ( 2008;). Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004. . J Clin Microbiol 46:, 79–86. [CrossRef][PubMed]
    [Google Scholar]
  18. Luca-Harari B., Darenberg J., Neal S., Siljander T., Strakova L., Tanna A., Creti R., Ekelund K., Koliou M.. & other authors ( 2009;). Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. . J Clin Microbiol 47:, 1155–1165. [CrossRef][PubMed]
    [Google Scholar]
  19. Ma Y., Yang Y., Huang M., Wang Y., Chen Y., Deng L., Yu S., Deng Q., Zhang H.. & other authors ( 2009;). Characterization of emm types and superantigens of Streptococcus pyogenes isolates from children during two sampling periods. . Epidemiol Infect 137:, 1414–1419. [CrossRef][PubMed]
    [Google Scholar]
  20. McMillan D. J., Drèze P. A., Vu T., Bessen D. E., Guglielmini J., Steer A. C., Carapetis J. R., Van Melderen L., Sriprakash K. S., Smeesters P. R.. ( 2013;). Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. . Clin Microbiol Infect 19:, E222–E229. [CrossRef][PubMed]
    [Google Scholar]
  21. Meisal R., Andreasson I. K. G., Høiby E. A., Aaberge I. S., Michaelsen T. E., Caugant D. A.. ( 2010;). Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm types, multilocus sequence types, and superantigen profiles. . J Clin Microbiol 48:, 842–851. [CrossRef][PubMed]
    [Google Scholar]
  22. Mihaila-Amrouche L., Bouvet A., Loubinoux J.. ( 2004;). Clonal spread of emm type 28 isolates of Streptococcus pyogenes that are multiresistant to antibiotics. . J Clin Microbiol 42:, 3844–3846. [CrossRef][PubMed]
    [Google Scholar]
  23. Mitchell D. T., Levitt D. G., Schlievert P. M., Ohlendorf D. H.. ( 2000;). Structural evidence for the evolution of pyrogenic toxin superantigens. . J Mol Evol 51:, 520–531. [CrossRef][PubMed]
    [Google Scholar]
  24. Musser J. M., Hauser A. R., Kim M. H., Schlievert P. M., Nelson K., Selander R. K.. ( 1991;). Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. . Proc Natl Acad Sci U S A 88:, 2668–2672. [CrossRef][PubMed]
    [Google Scholar]
  25. Mzoughi R., Bouallègue O., Selmi H., Ben Said H., Essoussi A. S., Jeddi M.. ( 2004;). Group A streptococci in children with acute pharyngitis in Sousse, Tunisia. . East Mediterr Health J 10:, 488–493.[PubMed]
    [Google Scholar]
  26. Ndiaye A. G., Sarr N. D. C., Thiam K., Boye C. S.. ( 2009;). In vitro activity of antimicrobial agents against Streptococcus pyogenes isolates from patients with acute tonsillopharyngitis in Dakar, Senegal. . Microbiol Ins 2, 25–29.
    [Google Scholar]
  27. Nielsen H. U., Hammerum A. M., Ekelund K., Bang D., Pallesen L. V., Frimodt-Møller N.. ( 2004;). Tetracycline and macrolide co-resistance in Streptococcus pyogenes: co-selection as a reason for increase in macrolide-resistant S. pyogenes?. Microb Drug Resist 10:, 231–238. [CrossRef][PubMed]
    [Google Scholar]
  28. Nir-Paz R., Korenman Z., Ron M., Michael-Gayego A., Cohen-Poradosu R., Valinsky L., Beall B., Moses A. E.. ( 2010;). Streptococcus pyogenes emm and T types within a decade, 1996–2005: implications for epidemiology and future vaccines. . Epidemiol Infect 138:, 53–60. [CrossRef][PubMed]
    [Google Scholar]
  29. Proft T., Moffatt S. L., Berkahn C. J., Fraser J. D.. ( 1999;). Identification and characterization of novel superantigens from Streptococcus pyogenes. . J Exp Med 189:, 89–102. [CrossRef][PubMed]
    [Google Scholar]
  30. Proft T., Arcus V. L., Handley V., Baker E. N., Fraser J. D.. ( 2001;). Immunological and biochemical characterization of streptococcal pyrogenic exotoxins I and J (SPE-I and SPE-J) from Streptococcus pyogenes. . J Immunol 166:, 6711–6719. [CrossRef][PubMed]
    [Google Scholar]
  31. Proft T., Webb P. D., Handley V., Fraser J. D.. ( 2003;). Two novel superantigens found in both group A and group C Streptococcus. . Infect Immun 71:, 1361–1369. [CrossRef][PubMed]
    [Google Scholar]
  32. Rantala S., Vähäkuopus S., Siljander T., Vuopio J., Huhtala H., Vuento R., Syrjänen J.. ( 2012;). Streptococcus pyogenes bacteraemia, emm types and superantigen profiles. . Eur J Clin Microbiol Infect Dis 31:, 859–865. [CrossRef][PubMed]
    [Google Scholar]
  33. Rivera A., Rebollo M., Miró E., Mateo M., Navarro F., Gurguí M., Mirelis B., Coll P.. ( 2006;). Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain. . J Med Microbiol 55:, 1115–1123. [CrossRef][PubMed]
    [Google Scholar]
  34. Smeesters P. R., McMillan D. J., Sriprakash K. S., Georgousakis M. M.. ( 2009;). Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?. Expert Rev Vaccines 8:, 1705–1720. [CrossRef][PubMed]
    [Google Scholar]
  35. Smoot L. M., McCormick J. K., Smoot J. C., Hoe N. P., Strickland I., Cole R. L., Barbian K. D., Earhart C. A., Ohlendorf D. H.. & other authors ( 2002;). Characterization of two novel pyrogenic toxin superantigens made by an acute rheumatic fever clone of Streptococcus pyogenes associated with multiple disease outbreaks. . Infect Immun 70:, 7095–7104. [CrossRef][PubMed]
    [Google Scholar]
  36. Staali L., Bauer S., Mörgelin M., Björck L., Tapper H.. ( 2006;). Streptococcus pyogenes bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes. . Cell Microbiol 8:, 690–703. [CrossRef][PubMed]
    [Google Scholar]
  37. Steer A. C., Law I., Matatolu L., Beall B. W., Carapetis J. R.. ( 2009;). Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. . Lancet Infect Dis 9:, 611–616. [CrossRef][PubMed]
    [Google Scholar]
  38. Villaseñor-Sierra A., Katahira E., Jaramillo-Valdivia A. N., Barajas-García Mde. L., Bryant A., Morfín-Otero R., Márquez-Díaz F., Tinoco J. C., Sánchez-Corona J., Stevens D. L.. ( 2012;). Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains isolated from invasive and non-invasive infections from Mexico and the USA during 1999-2010. . Int J Infect Dis 16:, e178–e181. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.063412-0
Loading
/content/journal/jmm/10.1099/jmm.0.063412-0
Loading

Data & Media loading...

Supplements

Supplementary Material 

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error